Cagrilintide

Cagrilintide is a long-acting amylin mimetic (37-aa peptide) and im glucagon-like peptide-1 (GLP-1) co-agonist, designed by Novo Nordisk to amplify satiety and metabolic control. With a fatty diacid chain for weekly dosing (half-life 7 days), it delivers 15–20% weight loss solo—up to 25%+ combined with semaglutide (CagriSema). Phase 3 trials position it as obesity’s next pillar.

Edge: Amylin slows emptying + GLP-1 brain signaling = unmatched fullness.

Development and Structure

Amylin (islet amyloid polypeptide) complements insulin; cagrilintide optimizes:

• Modifications: Lys33PAL + Aib substitutions → albumin binding.
• Receptors: AMY-R (70%), GLP-1R/CalCR (synergy).
• Differentiation: Pure amylin > pramlintide (Symlin).

Mechanism: Amylin-GLP-1 Synergy

1. Gastric Emptying: Amylin slows to max (area-under-curve ↓80%).
2. Hypothalamic Satiety: Area postrema → 50% calorie intake ↓.
3. Glucose Control: Insulin sensitization, glucagon suppression.
4. Adipose: Browning potential.

Vs. GLP-1 Monos:

Clinical Trial Data

Phase 2 (Lancet 2021, n=57)

CagriSema Phase 2 (NEJM 2023)

• Cagri 2.4mg + Sema 2.4mg: -22.7% (68w) vs. Sema -15.7%.

REDEFINE-1 Phase 3 (2024 Interim)

• CagriSema: -25% est. vs. ~17% GLP-1s.

Metabolic: A1C -2%, liver fat -70%.

Dosing Protocols (Trial-Based)

• Combo (CagriSema): Fixed-ratio pen.

Benefits: Amylin Unleashed

1. Weight Loss: Muscle-sparing (vs. GLP-1’s 40% lean loss).
2. Satiety King: “No hunger” reports 80%.
3. T2D/NASH: Superior glycemic/lipid control.
4. QoL: Cravings obliterated.
5. Synergy: Amplifies all incretins.

Side Effects Profile

• GI Advantage: Slower titration = 10% lower dropout.

Comparisons: Cagrilintide Ecosystem

Access and Status

• Development: Phase 3 complete 2025; approval 2026.
• UK: Trial access; private post-approval.
• Ex-US: Novo global push.

Pipeline Synergies

• CagriSema: Semaglutide fixed-ratio (priority).
• Triple +: Glucagon investigational.
• Oral: Preclinical.

Conclusion: Cagrilintide’s Satiety Revolution

Dual amylin-GLP unlocks metabolic ceilings—25% loss beckons. Watch REDEFINE readouts.